Compounds > 1-hexadecyl-2-acetyl-glycero-3-phosphocholine
Page last updated: 2024-09-02

1-hexadecyl-2-acetyl-glycero-3-phosphocholine and dipalmitoylphosphatidylcholine, hexadecanol, tyloxapol drug combination

1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with dipalmitoylphosphatidylcholine, hexadecanol, tyloxapol drug combination in 1 studies

Compound Research Comparison

Studies
(1-hexadecyl-2-acetyl-glycero-3-phosphocholine)		Trials
(1-hexadecyl-2-acetyl-glycero-3-phosphocholine)		Recent Studies (post-2010)
(1-hexadecyl-2-acetyl-glycero-3-phosphocholine)		Studies
(dipalmitoylphosphatidylcholine, hexadecanol, tyloxapol drug combination)		Trials
(dipalmitoylphosphatidylcholine, hexadecanol, tyloxapol drug combination)		Recent Studies (post-2010) (dipalmitoylphosphatidylcholine, hexadecanol, tyloxapol drug combination)
9,156187552219843

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hoffman, DR; Johnston, JM; Moya, FR; Zhao, B1

Other Studies

1 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and dipalmitoylphosphatidylcholine, hexadecanol, tyloxapol drug combination

ArticleYear
Platelet-activating factor in surfactant preparations.
    Lancet (London, England), 1993, Apr-03, Volume: 341, Issue:8849

    Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Animals; Biological Products; Drug Combinations; Fatty Alcohols; Humans; Infant, Newborn; Phospholipases A; Phospholipids; Phosphorylcholine; Platelet Activating Factor; Polyethylene Glycols; Pulmonary Surfactants; Respiratory Distress Syndrome, Newborn; Trachea

1993